Edition:
United States

Achaogen Inc (AKAO.OQ)

AKAO.OQ on NASDAQ Stock Exchange Global Market

10.92USD
21 Feb 2018
Change (% chg)

-- (--)
Prev Close
$10.92
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
293,671
52-wk High
$27.78
52-wk Low
$9.83

Chart for

About

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the... (more)

Overall

Beta: 1.21
Market Cap(Mil.): $462.94
Shares Outstanding(Mil.): 42.39
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 187.16 16.73
EPS (TTM): -- -- --
ROI: -- -0.71 35.60
ROE: -- -3.52 17.23

BRIEF-Achaogen Announces Upgraded Status For Plazomicin Fill Manufacturer

* SAYS ‍FDA CLASSIFIED OUTCOME OF ITS Q4 2017 REINSPECTION OF PFIZER'S MCPHERSON FACILITY AS VOLUNTARY ACTION INDICATED​ Source text for Eikon: Further company coverage:

Jan 30 2018

BRIEF-Achaogen Announces Positive Top-Line Results From First Clinical Trial Of Orally-Administered Antibacterial Candidate C-Scape

* ACHAOGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM FIRST CLINICAL TRIAL OF ORALLY-ADMINISTERED ANTIBACTERIAL CANDIDATE C-SCAPE

Jan 02 2018

BRIEF-Achaogen Announces FDA Acceptance Of New Drug Application With Priority Review For Plazomicin

* ACHAOGEN ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION WITH PRIORITY REVIEW FOR PLAZOMICIN FOR TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND BLOODSTREAM INFECTIONS

Jan 02 2018

BRIEF-Achaogen Appoints Blake Wise Chief Executive Officer

* ACHAOGEN INC - KENNETH HILLAN TO BECOME PRESIDENT, RESEARCH AND DEVELOPMENT

Dec 11 2017

BRIEF-Achaogen reports Q3 loss per share $0.85

* Achaogen reports third quarter 2017 financial results and provides corporate update

Nov 08 2017

BRIEF-Achaogen submits Plazomicin new drug application to FDA

* Achaogen submits Plazomicin new drug application (NDA) to the U.S. FDA for treatment of complicated urinary tract infections and bloodstream infections

Oct 26 2017

BRIEF-Achaogen awarded up to $18 million contract by BARDA

* Achaogen awarded up to $18 million contract by BARDA to support development of orally-administered antibacterial candidate C-Scape

Sep 28 2017

Earnings vs. Estimates